Eye on ESMO: Day 2 – gamechangers take centre stage
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
Winners plan to build a corporate social responsibility programme around clinical trial recruitment.